Overal Survival After TAVI According to Sarcopenia

The goal of this observational study is to compare the overal survival after transcatheter aortic valve implantation (TAVI) according to sarcopenia status evaluated from preprocedural CT scans.

The main question it aims to answer is:

• Is CT evaluated sarcopenia an independent predictor of overal survival after TAVI?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenia Aortic Valve Disease Aortic Valve Stenosis Atrophy Cardiovascular Diseases Heart Diseases Heart Valve Diseases Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms Ventricular Outflow Obstruction

Sex eligibility

All sexes

Study type

Observational

Primary location

AGELTrinecPodlesi

Třinec, Česká Republika, 73961, Czechia

About this study

The patients suffering from aortic valve stenosis, that are not eligible for cardiosurgery were indicated to miniinvasive transcatheter aortic valve implantation (TAVI). The follow up of 930 patients were done in time interval from 1 to 11 years. In every patient the preprocedural CT scans were done. From these CT scans the L3 cross sections will be used for sarcopenia evaluation. Then we will statisticaly evaluate the overal survival after TAVI procedure in the relation with sarcopenia status. We will answer the main question: Is CT evaluated sarcopenia an independent predictor of overal survival after TAVI?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients udergone TAVI procedure

Exclusion criteria

patients with incomplete TAVI procedure, patients without clinical follow up

Treatment and study plan

CT evaluated sarcopenia

Diagnostic Test

At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.

Primary outcomes

Overal survival

Time frame: 11 years

Time from the TAVI procedure to death

Sponsors and collaborators

Lead sponsor

Nemocnice AGEL Trinec-Podlesi a.s.

Other

Registry information

Official study title

CT Evaluated Sarcopenia Independently Predicts the Overal Survival After Transcatheter Aortic Valve Implantation

Acronym: TAVI_Sarx

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jan 5, 2023
Registry last updated: Jan 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed